Literature DB >> 25219588

A genetic analysis of the validity of the Hypomanic Personality Scale.

Sheri L Johnson1, Charles S Carver, Jutta Joormann, Michael Cuccaro.   

Abstract

OBJECTIVES: Studies of mania risk have increasingly relied on measures of subsyndromal tendencies to experience manic symptoms. The measures of mania risk employed in those studies have been shown to predict manic onset, to show familial associations, and to demonstrate expected correlations with psychosocial variables related to bipolar disorder. However, little work has been conducted to validate such measures against biologically relevant indices, or to consider whether early adversity, which has been shown to be highly elevated among those with bipolar disorder, is related to higher scores on mania risk measures. This study tested whether a well-used, self-report measure of vulnerability to mania is associated with several candidate genes that have previously been linked with bipolar disorder or with early adversity. Interactions of genes with early adversity in the prediction of mania vulnerability were also tested.
METHODS: Undergraduate students from the University of Miami (Coral Gables, FL, USA) (N = 305) completed the Hypomanic Personality Scale and the Risky Families Scale, and provided blood for genotyping.
RESULTS: Findings indicated that the Hypomanic Personality Scale was related to a number of dopamine-relevant polymorphisms and with early adversity. A polymorphism of ANKK1 appeared to specifically increase mania risk in the context of early adversity.
CONCLUSIONS: These results provide additional support for the validity of the Hypomanic Personality Scale.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bipolar disorder; dopamine; early adversity; genetic polymorphism; mania risk

Mesh:

Substances:

Year:  2014        PMID: 25219588     DOI: 10.1111/bdi.12251

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  7 in total

1.  Creativity is linked to ambition across the bipolar spectrum.

Authors:  Sheri L Johnson; Greg Murray; Sharon Hou; Paige J Staudenmaier; Michael A Freeman; Erin E Michalak
Journal:  J Affect Disord       Date:  2015-03-05       Impact factor: 4.839

2.  Hypomania and saccadic changes in Parkinson's disease: influence of D2 and D3 dopaminergic signalling.

Authors:  Esther A Pelzer; Barbara Dillenburger; Sophie Grundmann; Vladimir Iliaev; Sophie Aschenberg; Corina Melzer; Martin Hess; Gereon R Fink; Carsten Eggers; Marc Tittgemeyer; Lars Timmermann
Journal:  NPJ Parkinsons Dis       Date:  2020-01-17

3.  Emotion regulation and mania risk: Differential responses to implicit and explicit cues to regulate.

Authors:  Yatrika Ajaya; Andrew D Peckham; Sheri L Johnson
Journal:  J Behav Ther Exp Psychiatry       Date:  2015-10-23

4.  Looking on the bright side and seeing it vividly: interpretation bias and involuntary mental imagery are related to risk for bipolar disorder.

Authors:  Andrew D Peckham; Kiana Modavi; Sheri L Johnson
Journal:  Behav Cogn Psychother       Date:  2019-10-10

Review 5.  Deficits in explicit emotion regulation in bipolar disorder: a systematic review.

Authors:  Marcel Kurtz; Pia Mohring; Katharina Förster; Michael Bauer; Philipp Kanske
Journal:  Int J Bipolar Disord       Date:  2021-05-03

6.  Hypomania and saccadic changes in Parkinson's disease: influence of D2 and D3 dopaminergic signalling.

Authors:  Esther A Pelzer; Barbara Dillenburger; Sophie Grundmann; Vladimir Iliaev; Sophie Aschenberg; Corina Melzer; Martin Hess; Gereon R Fink; Carsten Eggers; Marc Tittgemeyer; Lars Timmermann
Journal:  NPJ Parkinsons Dis       Date:  2020-01-17

7.  Vulnerability to bipolar disorder is linked to sleep and sleepiness.

Authors:  Tilman Hensch; David Wozniak; Janek Spada; Christian Sander; Christine Ulke; Dirk Alexander Wittekind; Joachim Thiery; Markus Löffler; Philippe Jawinski; Ulrich Hegerl
Journal:  Transl Psychiatry       Date:  2019-11-11       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.